Shibu Thomas

2.4k total citations
71 papers, 1.5k citations indexed

About

Shibu Thomas is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Shibu Thomas has authored 71 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Pulmonary and Respiratory Medicine, 25 papers in Cancer Research and 23 papers in Molecular Biology. Recurrent topics in Shibu Thomas's work include Prostate Cancer Treatment and Research (34 papers), Radiopharmaceutical Chemistry and Applications (18 papers) and Cancer, Lipids, and Metabolism (13 papers). Shibu Thomas is often cited by papers focused on Prostate Cancer Treatment and Research (34 papers), Radiopharmaceutical Chemistry and Applications (18 papers) and Cancer, Lipids, and Metabolism (13 papers). Shibu Thomas collaborates with scholars based in United States, United Kingdom and France. Shibu Thomas's co-authors include Girish V. Shah, Dan Theodorescu, Jonathan B. Overdevest, Steven C. Smith, Muralidharan Anbalagan, Matthew D. Nitz, Henry F. Frierson, Glen Kristiansen, Michael A. Harding and Srinivasulu Chigurupati and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Shibu Thomas

63 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shibu Thomas United States	21	634	521	412	348	141	71	1.5k
Wilhelmina Duivenvoorden Canada	20	431 0.7×	401 0.8×	374 0.9×	293 0.8×	94 0.7×	49	1.2k
Xinxin Zhang China	18	684 1.1×	436 0.8×	517 1.3×	318 0.9×	127 0.9×	76	1.5k
Peihua Luo China	28	934 1.5×	300 0.6×	465 1.1×	190 0.5×	85 0.6×	94	1.8k
Chang Hun Rhee South Korea	22	968 1.5×	196 0.4×	287 0.7×	405 1.2×	194 1.4×	34	1.8k
Jun Cao China	23	810 1.3×	336 0.6×	562 1.4×	418 1.2×	113 0.8×	74	1.6k
Daqing Wu United States	24	942 1.5×	329 0.6×	460 1.1×	279 0.8×	104 0.7×	56	1.7k
Francesca Bruzzese Italy	24	1.2k 1.9×	293 0.6×	593 1.4×	308 0.9×	131 0.9×	55	1.7k
Yuanyuan Qu China	22	811 1.3×	739 1.4×	343 0.8×	530 1.5×	200 1.4×	81	1.6k
Tingting Zhao China	25	759 1.2×	157 0.3×	314 0.8×	288 0.8×	169 1.2×	74	1.5k
Xiaoling Du China	24	605 1.0×	461 0.9×	339 0.8×	277 0.8×	76 0.5×	53	1.3k

Countries citing papers authored by Shibu Thomas

Since Specialization

Citations

This map shows the geographic impact of Shibu Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shibu Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shibu Thomas more than expected).

Fields of papers citing papers by Shibu Thomas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shibu Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shibu Thomas. The network helps show where Shibu Thomas may publish in the future.

Co-authorship network of co-authors of Shibu Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Shibu Thomas. A scholar is included among the top collaborators of Shibu Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shibu Thomas. Shibu Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Siefker‐Radtke, Arlene O., Yohann Loriot, Nobuaki Matsubara, et al.. (2024). FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).. Journal of Clinical Oncology. 42(16_suppl). 4578–4578.

Pant, Shubham, Joon Oh Park, Wu‐Chou Su, et al.. (2024). Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies.. Journal of Clinical Oncology. 42(16_suppl). 4121–4121. 1 indexed citations

Pant, Shubham, Dirk Arnold, Josep Tabernero, et al.. (2023). 1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial. Annals of Oncology. 34. S898–S898. 2 indexed citations

Reardon, David A., Liam Welsh, Kent C. Shih, et al.. (2023). CTNI-64. EFFICACY AND SAFETY OF ERDAFITINIB IN PATIENTS WITH HIGH-GRADE AND LOW-GRADE GLIOMAS AND PRESPECIFIED FIBROBLAST GROWTH FACTOR RECEPTOR ALTERATIONS (FGFRALT) IN THE RAGNAR TRIAL. Neuro-Oncology. 25(Supplement_5). v91–v91.

Sweiti, Hussein, Spyros Triantos, Shibu Thomas, et al.. (2023). 192P Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting. Annals of Oncology. 34. S259–S259.

Smith, Matthew R., Shibu Thomas, Michael Gormley, et al.. (2021). Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. Clinical Cancer Research. 27(16). 4539–4548. 9 indexed citations

Saad, Fred, Eric J. Small, Felix Y. Feng, et al.. (2021). Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. European Urology. 81(2). 184–192. 35 indexed citations

Feng, Felix Y., Shibu Thomas, Fred Saad, et al.. (2021). Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Oncology. 7(7). 1005–1005. 21 indexed citations

Jayaram, Anuradha, Anna Wingate, Daniel Wetterskog, et al.. (2021). Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. Annals of Oncology. 32(6). 726–735. 36 indexed citations

10.

Saad, Fred, Eleni Efstathiou, Gerhardt Attard, et al.. (2021). Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. The Lancet Oncology. 22(11). 1541–1559. 64 indexed citations

11.

Lam, Hung‐Ming, Ryan P. McMullin, Holly M. Nguyen, et al.. (2016). Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. Clinical Cancer Research. 23(9). 2301–2312. 17 indexed citations

12.

Thomas, Shibu, Michael A. Harding, Steven C. Smith, et al.. (2012). CD24 Is an Effector of HIF-1–Driven Primary Tumor Growth and Metastasis. Cancer Research. 72(21). 5600–5612. 117 indexed citations

13.

Overdevest, Jonathan B., Shibu Thomas, Glen Kristiansen, et al.. (2011). CD24 Offers a Therapeutic Target for Control of Bladder Cancer Metastasis Based on a Requirement for Lung Colonization. Cancer Research. 71(11). 3802–3811. 97 indexed citations

14.

Nitz, Matthew D., Michael A. Harding, Steven C. Smith, Shibu Thomas, & Dan Theodorescu. (2011). RREB1 Transcription Factor Splice Variants in Urologic Cancer. American Journal Of Pathology. 179(1). 477–486. 17 indexed citations

15.

Thomas, Shibu, Jonathan B. Overdevest, Matthew D. Nitz, et al.. (2010). Src and Caveolin-1 Reciprocally Regulate Metastasis via a Common Downstream Signaling Pathway in Bladder Cancer. Cancer Research. 71(3). 832–841. 79 indexed citations

16.

Shah, Girish V., Muralidharan Anbalagan, Shibu Thomas, et al.. (2009). Identification of a small molecule class to enhance cell-cell adhesion and attenuate prostate tumor growth and metastasis. Molecular Cancer Therapeutics. 8(3). 509–520. 29 indexed citations

17.

Thomas, Shibu, et al.. (2007). A validated stability indicating HPTLC method for determination of nitazoxanide. Journal of Scientific & Industrial Research. 66(2). 141–145. 10 indexed citations

18.

Chigurupati, Srinivasulu, et al.. (2005). Calcitonin Stimulates Multiple Stages of Angiogenesis by Directly Acting on Endothelial Cells. Cancer Research. 65(18). 8519–8529. 36 indexed citations

19.

Sabbisetti, Venkata, Srinivasulu Chigurupati, Shibu Thomas, & Girish V. Shah. (2005). Calcitonin stimulates the secretion of urokinase‐type plasminogen activator from prostate cancer cells: Its possible implications on tumor cell invasion. International Journal of Cancer. 118(11). 2694–2702. 10 indexed citations

20.

Sabbisetti, Venkata, Shibu Thomas, Kedar S. Vaidya, et al.. (2005). Calcitonin increases invasiveness of prostate cancer cells: Role for cyclic AMP-dependent protein kinase A in calcitonin action. International Journal of Cancer. 117(4). 551–560. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact